Maze Therapeutics, Inc Common Stock
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -649 | -684 | -705 | |
EBITDA | -29,516 | -33,030 | -34,717 | -29,021 |
EBIT | -30,087 | -33,679 | -35,401 | -29,726 |
Net Income | -30,087 | -33,679 | -32,786 | -29,579 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -24,710 | -30,445 | -29,815 | -23,057 |
Cash | 316,773 | 264,541 | 294,374 | 196,812 |
Basic Shares | 45,779 | 43,850 | 43,797 | 43,796 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
Revenue | $167,500 | $0 | $0 |
Gross Profit | 167,500 | -4,089 | -3,820 |
EBITDA | 60,883 | -94,462 | -107,206 |
EBIT | 57,586 | -98,551 | -111,026 |
Net Income | 52,231 | -100,415 | -114,940 |
Net Change In Cash | 167,500 | 0 | 0 |
Free Cash Flow | 74,807 | -87,268 | -101,169 |
Cash | 196,812 | 29,158 | 99,919 |
Basic Shares | 43,796 | 43,776 | 43,776 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.66 |
2025-06-30 | -$0.77 |
2025-03-31 | -$1.15 |
2024-12-31 | -$18.32 |
